Diabetes drug halves risk of heart failure

The effect appears consistent in patients with or without CVD, a real-world study shows

Patients with type 2 diabetes (with and without cardiovascular disease) who are taking empagliflozin have half the risk of being hospitalised for heart failure compared with similar patients on sitagliptin, a US study shows.